Peptide LibraryHumanin-G (HNG)
Humanin-G (HNG) is a potent humanin analog in the Mitochondrial Peptide class. Humanin is encoded within the mitochondrial 16S rRNA gene and acts both intracellularly, by interfering with Bax-mediated apoptosis, and extracellularly through a receptor complex involving CNTFR, WSX-1 and gp130.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
Research summary
Analog of the mitochondrial-derived peptide humanin carrying a serine-to-glycine substitution at position 14, reported in preclinical work to be substantially more potent than the parent peptide. Not FDA-approved; no human trials.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studies2 reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Humanin-G (HNG) profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Humanin-G (HNG) dosage: no established human dose
Humanin-G (HNG) has no established human dosage. It is an engineered, more potent form of humanin with glycine at position 14, and it has only been given to animals. In mice it has been injected into the abdominal cavity at 4 mg/kg twice a week for 14 months in an ageing-heart study and at 10 mg/kg in an ovarian-insufficiency study.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: HNG is a version of the mitochondrial peptide humanin with one amino acid changed to make it much more potent. All in vivo dosing is in rodents, by intraperitoneal injection and in mg/kg, which does not convert to a human dose. No human study has given HNG by any route.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Preclinical — HNG and age-related heart fibrosis in mice (2018)Preclinical · Animal study | Female mice aged 18 months | 4 mg/kg (non-human) | Intraperitoneal | Twice weekly | 14 months | Less age-related heart fibrosis than in untreated old mice | Chronic treatment with the mitochondrial peptide humanin prevents age-related myocardial fibrosis in mice. Am J Physiol Heart Circ Physiol. 2018. |
| Preclinical — HNG in D-galactose-induced ovarian insufficiency in mice (2024)Preclinical · Animal study | Mice | 10 mg/kg was the effective dose among those tested (non-human) | Intraperitoneal | — | — | Protection against D-galactose-induced ovarian insufficiency | [Gly14]-humanin exerts a protective effect against D-galactose-induced primary ovarian insufficiency in mice. Reprod Biomed Online. 2024. |
Where sources disagree
- HNG and native humanin are different compounds with different potency. Doses for one are not doses for the other; the native-humanin profile covers humanin itself.
- Human studies that mention humanin measure the body's own humanin as a marker, for example after exercise. They do not give HNG and are not dosing evidence.
Reconstitution
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Science
Mechanism of Action
Humanin is encoded within the mitochondrial 16S rRNA gene and acts both intracellularly, by interfering with Bax-mediated apoptosis, and extracellularly through a receptor complex involving CNTFR, WSX-1 and gp130. The S14G substitution increases cytoprotective potency in cell and rodent models by orders of magnitude relative to wild-type humanin, which is why it is the form most often used in research.
Studies
- Humanin G (HNG) protects age-related macular degeneration (AMD) transmitochondrial ARPE-19 cybrids from mitochondrial and cellular damage
- Humanin-G protects septic ARDS by mediating mitochondrial function in lung vascular endothelial cells
- S14G-humanin (HNG) ameliorates diabetic nephropathy tubular injury by inhibiting Z-DNA/ZBP1-mediated necroptosis
- Neuroprotective Effect of Intraperitoneal Humanin-G in Retinal Degeneration of Royal College of Surgeons Rats
- Neuroprotective effect of intraperitoneal Humanin-G in retinal degeneration of Royal College of Surgeons rats
Research statistics
41 PubMed publications · 2.4% human clinical research · 0 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Humanin-G (HNG) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Research status | Research-only compound; no approval pathway listed |
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
—
Humanin-G (HNG) side effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Humanin-G (HNG): frequently asked questions
What is Humanin-G (HNG)?
Analog of the mitochondrial-derived peptide humanin carrying a serine-to-glycine substitution at position 14, reported in preclinical work to be substantially more potent than the parent peptide. Not FDA-approved; no human trials.
How does Humanin-G (HNG) work?
Humanin is encoded within the mitochondrial 16S rRNA gene and acts both intracellularly, by interfering with Bax-mediated apoptosis, and extracellularly through a receptor complex involving CNTFR, WSX-1 and gp130. The S14G substitution increases cytoprotective potency in cell and rodent models by orders of magnitude relative to wild-type humanin, which is why it is the form most often used in research.
Is Humanin-G (HNG) FDA approved?
No. Humanin-G (HNG) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to Humanin-G (HNG)?
Compounds most often compared with Humanin-G (HNG) include MOTS-C, Humanin, SS-20 and Elamipretide (SS-31). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Humanin G (HNG) protects age-related macular degeneration (AMD) transmitochondrial ARPE-19 cybrids from mitochondrial and cellular damage — Cell Death Dis, 2017External reference
- Humanin-G protects septic ARDS by mediating mitochondrial function in lung vascular endothelial cells — Am J Respir Cell Mol Biol, 2026External reference
- S14G-humanin (HNG) ameliorates diabetic nephropathy tubular injury by inhibiting Z-DNA/ZBP1-mediated necroptosis — Eur J Pharmacol, 2026External reference
- Neuroprotective Effect of Intraperitoneal Humanin-G in Retinal Degeneration of Royal College of Surgeons Rats — Res Sq, 2026External reference
- Neuroprotective effect of intraperitoneal Humanin-G in retinal degeneration of Royal College of Surgeons rats — Sci Rep, 2026External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This Humanin-G (HNG) profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Humanin-G (HNG) research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →